Goldman Sachs Reiterates Overweight on Immunocore Hldgs, Maintains $79 Price Target
Portfolio Pulse from Benzinga Newsdesk
Goldman Sachs analyst Rajan Sharma reiterated an Overweight rating on Immunocore Holdings (NASDAQ: IMCR) and maintained a $79 price target.

June 20, 2023 | 1:08 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Goldman Sachs analyst Rajan Sharma reiterated an Overweight rating on Immunocore Holdings (NASDAQ: IMCR) and maintained a $79 price target.
The reiteration of an Overweight rating by Goldman Sachs analyst Rajan Sharma indicates a positive outlook for Immunocore Holdings. The maintained $79 price target suggests that the stock is expected to perform well in the short term. This news is highly relevant and important for investors in IMCR, as it comes from a reputable financial institution and analyst.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100